
CFA Institute’s new continuation-fund report exposes a bigger pension problem: GP-controlled transactions can potentially manufacture valuations, move performance between funds, crystallize carry and turn smoothed private-market marks into something that looks like independent price discovery.
Private equity already has a valuation problem. https://rpc.cfainstitute.org/sites/default/files/docs/research-reports/continuation-funds-ii_online.pdf
Now it may have found a way to make that valuation problem look like a market transaction.
In my recent CommonSense piece, “Private Equity’s New 401(k) Sales Pitch: Fake Diversification From Smoothed Numbers,” I explained the basic problem:
Smoothed NAV → artificially low measured volatility → artificially low correlation → artificially attractive Sharpe ratio → apparent diversification benefit.
Private equity doesn’t necessarily become less risky because its reported price moves less often.
The ruler changed.
Now a new CFA Institute report on continuation funds raises an even more troubling question:
What happens when the private-equity manager can effectively sell an asset from one fund it manages to another fund it manages—and then point to that transaction as evidence of value?
That matters to public pensions today.
It matters to insurance-company portfolios stuffed with private assets.
And as Wall Street pushes private equity and private credit into 401(k) target-date funds, it could become an enormous ERISA fiduciary problem.
What Is a Continuation Fund?
The basic transaction isn’t complicated.
A private-equity GP owns a company through an existing fund.
Normally we would expect the eventual exit to be something like:
PE Fund → Independent Buyer → Cash
The independent buyer establishes something approaching a real market price.
A continuation transaction can look very different:
Old PE Fund
↓
Portfolio Company
↓
Continuation Fund controlled by the same GP
↓
Same Portfolio Company
Existing investors may cash out or roll their interests into the continuation vehicle. New investors may come in.
But the GP can remain in control of the asset before and after the transaction.
That means something extraordinary has happened:
The GP is effectively involved on both sides of the transaction.
CFA Institute’s new report doesn’t dismiss this conflict. It puts it front and center.
The GP may organize the sale process, negotiate the price, manage the legacy fund selling the asset and then manage the continuation vehicle buying it.
That’s not necessarily wrongdoing.
But don’t call it the equivalent of selling Ford stock on the New York Stock Exchange.
The Manager Can Have an Incentive for a High Price—or a Low Price
This is one of the most fascinating parts of the CFA report.
You might assume a PE manager always wants the highest possible valuation.
Not necessarily.
A higher continuation-fund price can benefit the legacy fund.
It may:
- improve reported returns;
- increase DPI;
- increase IRR;
- crystallize carried interest;
- strengthen the GP’s historical track record; and
- make the manager look better when raising its next fund.
But the GP can also have reasons to favor a lower transaction price.
A lower purchase price gives the continuation fund a lower starting basis.
That potentially creates more upside in the new vehicle—and another opportunity for future carried interest.
Think about what that means.
The manager doesn’t necessarily have a simple incentive to inflate the asset.
It can potentially have discretion over where it wants the performance to appear.
Legacy Fund A needs better performance?
A higher transaction value can help.
Continuation Fund B needs an attractive future return?
A lower starting value can help.
And the same GP can be involved with both funds.
That isn’t conventional price discovery.
It is a conflict that every pension trustee and ERISA fiduciary should understand.
From “Volatility Laundering” to “Transaction Laundering”
My August 15 article examined how stale and discretionary private-market valuations can produce an illusion of lower risk.
Public stocks are priced every trading day.
Private assets frequently aren’t.
If the S&P 500 drops 20%, we know it immediately.
A private-equity portfolio company may not receive a comparable markdown for weeks or months.
That produces the familiar chain:
Stale marks → lower reported volatility → lower measured correlation → better Sharpe ratio → apparent diversification.
An optimizer doesn’t know that one return series represents continuously traded securities while the other represents periodically estimated values.
It just sees numbers.
Garbage risk statistics in → fiduciary-looking efficient frontier out.
Continuation funds potentially add another layer.
Instead of:
GP estimate → NAV
we can get:
GP estimate → GP-organized transaction → GP-controlled continuation vehicle → “transaction price” → NAV
Suddenly an internally influenced valuation can acquire the appearance of external validation.
That is much more powerful.
The manager can say:
“This isn’t merely our mark. A transaction occurred at this price.”
Fine.
Then the fiduciary should ask:
Who was really on the other side of the transaction?
A $100 Million Example
Suppose a PE manager carries a company at:
$100 million.
Imagine a genuinely independent secondary buyer would pay only:
$85 million.
That’s important information.
The real market might be telling the pension fund that its $100 million asset is worth closer to $85 million.
But instead of accepting that independent-market discount, the GP organizes a continuation vehicle transaction at $100 million.
The legacy fund can now report something resembling a $100 million realization.
DPI may improve.
IRR may improve.
Carry may be crystallized.
The GP continues managing the company.
The continuation fund starts with a $100 million investment.
Five years later, suppose the company is finally sold to a truly independent buyer for $150 million.
Now the GP’s performance presentation can potentially tell two attractive stories:
Legacy fund: Successful $100 million realization.
Continuation fund: $100 million investment became $150 million.
But economically, the GP never really exited the investment at $100 million.
It moved the asset from one vehicle it managed to another vehicle it managed.
There may have been only one genuinely independent market price:
$150 million.
Public Pensions Should Be Particularly Concerned
This fits almost perfectly with CFA Institute research by Richard Ennis on what he calls “volatility laundering.”
Ennis looked at secondary-market discounts to reported private-market NAV.
The discounts he cited were striking:
| Asset | Approximate Secondary-Market Discount to NAV |
| Buyout | 6% |
| Private Credit | 15% |
| Real Estate | 26% |
| Venture Capital | 30% |
| All Private Assets | 12% |
That is a huge issue for public pensions.
If a pension reports a private asset at $100 million while independent secondary buyers would pay only $85 million, which number should taxpayers and trustees care about?
Probably both.
Yet the pension’s annual report may prominently display the $100 million NAV.
Continuation vehicles potentially complicate the problem further because a manager-controlled transaction may provide apparent support for the reported NAV. https://rpc.cfainstitute.org/blogs/enterprising-investor/2025/volatility-laundering-public-pension-funds-and-the-impact-of-nav-adjustments
This can potentially flow through the entire pension reporting system:
GP valuation
↓
Continuation transaction
↓
Pension NAV
↓
Private-equity return
↓
Total-fund return
↓
Benchmark comparison
↓
Reported “alpha”
↓
CIO/manager compensation
↓
Trustee and taxpayer perception
This isn’t merely an accounting technicality.
Performance numbers determine reputations, bonuses, asset allocations and hundreds of billions of dollars of future commitments.
Did the Pension Really Realize Anything?
Here’s another question pension trustees should start asking.
Suppose a pension owns the legacy fund.
The portfolio company moves into a continuation vehicle.
The pension elects to roll its investment.
Did the pension really experience an economic realization?
Or did an accounting event occur while substantially the same economic exposure continued?
Those aren’t necessarily the same thing.
A pension report showing improved DPI or a realization could leave trustees with a very different impression than:
We still own exposure to substantially the same company through another vehicle managed by substantially the same manager.
That distinction belongs in pension investment-committee minutes.
Insurance Companies May Be an Even Bigger Problem
Now apply this to insurance companies.
Insurance-company portfolios increasingly contain private credit, private equity, structured investments and other assets without transparent daily market prices.
In some cases the insurer, asset manager, private fund, financing entities and related investment vehicles can exist within interconnected corporate ecosystems.
That makes the valuation question extremely important.
A regulator, policyholder, pension fiduciary or annuity purchaser shouldn’t merely ask:
“Was there a transaction?”
They should ask:
“Was there a genuinely independent transaction capable of establishing fair market value?”
Those are very different questions.
If an affiliated or closely connected asset manager controls the investment before the transaction and continues controlling it afterward, calling the resulting number “market value” deserves scrutiny.
For an insurance company, asset values can ultimately affect perceptions of:
- investment performance;
- asset quality;
- capital strength;
- surplus;
- creditworthiness;
- liquidity; and
- the safety of liabilities backing annuities and retirement benefits.
This deserves considerably more attention from state insurance regulators.
Now Put This Inside a 401(k) Target-Date Fund
This is where continuation funds become an ERISA issue.
Wall Street wants the next generation of target-date funds to contain things like:
Public Stocks + Bonds + Private Equity + Private Credit + Real Estate + Annuities
The sales pitch is diversification.
But as I discussed in my August 15 CommonSense article, mixing daily-priced public securities with manager-valued private assets can produce misleading volatility and correlation statistics.
Now imagine some of those private investments also move through continuation vehicles.
The participant sees:
“2055 Target Retirement Fund.”
The investment committee sees:
“Improved diversification.”
Underneath that simple name could potentially sit:
401(k)
↓
Target-Date CIT
↓
Private-Market Fund
↓
PE Partnership
↓
Continuation Vehicle
↓
Portfolio Company
And somewhere down that chain somebody has to decide what that company is worth.
That valuation eventually works its way back into the participant’s retirement account.
ERISA Fiduciaries Cannot Outsource Common Sense
ERISA doesn’t require an investment committee to become an expert private-equity appraiser.
It does require a prudent process.
A fiduciary considering a target-date fund containing private assets should therefore understand how those assets are being valued.
Continuation funds make that obligation more important—not less.
A consultant shouldn’t be allowed to walk into an investment committee meeting and say:
“The asset was independently validated by a market transaction.”
without somebody asking:
Who controlled the seller?
Who controlled the buyer?
Who selected the bidders?
Who established the valuation?
Who received carried interest?
Who continued earning management fees afterward?
Those aren’t obscure technical questions.
They’re basic fiduciary questions.
The Plaintiff’s Discovery Request Almost Writes Itself
Suppose a 401(k) plan eventually gets sued over a target-date fund containing PE interests that participated in continuation transactions.
Plaintiff counsel should request:
- Legacy-fund NAV immediately before each continuation transaction.
- Continuation-fund transaction price.
- Every independent bid received.
- Bid-price ranges.
- Secondary-market indications of value.
- Fairness opinions and independent valuations.
- Valuation methodologies and assumptions.
- Changes in valuation methodology before the transaction.
- GP carried interest crystallized in the legacy fund.
- Carry terms in the continuation vehicle.
- Management fees before and after the transaction.
- Percentage of existing LPs that rolled.
- GP investment in the continuation vehicle.
- IRR and DPI immediately before and after the transaction.
- Performance presentations used in subsequent fundraising.
- Investment-consultant analysis presented to the ERISA committee.
- Any analysis comparing the transaction price with a genuine third-party sale.
Then ask one very simple deposition question:
“You called this a market transaction. Who was the independent buyer?”
The answer could become interesting.
Six Numbers Every Fiduciary Should Demand
My earlier CommonSense article suggested that before accepting the claim that private equity reduces target-date-fund risk, fiduciaries should demand six numbers:
Reported PE volatility.
Unsmoothed PE volatility.
Reported stock/PE correlation.
Unsmoothed stock/PE correlation.
Stress-period correlation.
Secondary-market discount to NAV.
Continuation funds justify adding several more:
Pre-transaction NAV.
Continuation transaction price.
Highest independent bid.
Lowest independent bid.
Carry crystallized at the transaction.
Legacy-fund IRR before and after the transaction.
Put those numbers side by side.
You may learn considerably more than you will from a 70-page consultant presentation.
Bottom Line
Private equity already has an enormous advantage over public markets:
It largely controls when changes in value appear in reported returns.
That can suppress measured volatility and correlation.
Continuation funds potentially add another advantage:
The manager can participate in creating a transaction around its own valuation.
That doesn’t mean every continuation fund is improper.
It doesn’t mean every continuation-fund price is manipulated.
And it certainly doesn’t mean every transaction violates ERISA.
But CFA Institute’s own analysis demonstrates why fiduciaries shouldn’t automatically treat these transactions as independent price discovery.
When the same manager can influence the seller, buyer, transaction process, valuation, carried interest and subsequent management of the asset, a transaction price deserves considerably more scrutiny than an ordinary arm’s-length sale.
For public pensions, the danger is that valuation smoothing can become performance smoothing.
For insurers, questionable private-market marks can potentially obscure the economic risk sitting behind retirement guarantees.
And for ERISA plans, the problem may eventually be even simpler:
A fiduciary can’t claim private equity reduces risk because its reported prices don’t move—and then accept a GP-controlled continuation transaction as proof that those same reported prices were market values.
Private equity doesn’t become less volatile because nobody marks it down.
And an estimated price doesn’t necessarily become a market price merely because the manager sells the asset to another fund it manages.
Sometimes the asset didn’t really leave.
Only the accounting did.








